Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Umbilical Cord Blood Transplantation From Unrelated Donors
- Conditions
- Interventions
- First Posted Date
- 2017-01-11
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 30
- Registration Number
- NCT03016806
- Locations
- 🇺🇸
Wilmot Cancer Institute, Rochester, New York, United States
2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
- Conditions
- Interventions
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2020-07-10
- Lead Sponsor
- University of Arkansas
- Registration Number
- NCT03003728
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
2015-12: a Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 50
- Registration Number
- NCT03004287
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma
- First Posted Date
- 2016-11-11
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT02961816
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Conditions
- Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAplastic AnemiaBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Myelomonocytic LeukemiaChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveLymphoblastic LymphomaMyelodysplastic SyndromeMyeloproliferative Neoplasm
- Interventions
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT02960646
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 18
- Registration Number
- NCT02917096
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance
- Conditions
- Interventions
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 86
- Registration Number
- NCT02896582
- Locations
- 🇫🇷
CHU d'Angers, Angers, France
🇫🇷CHU d'Amiens, Amiens, France
🇫🇷CH d'Avignon, Avignon, France
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
- Conditions
- Interventions
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT02880293
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Monica Bhatia
- Target Recruit Count
- 24
- Registration Number
- NCT02867800
- Locations
- 🇺🇸
North Carolina Cancer Hospital, Chapel Hill, North Carolina, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Conservative Treatments of Retinoblastoma
- Conditions
- Interventions
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Institut Curie
- Target Recruit Count
- 133
- Registration Number
- NCT02866136
- Locations
- 🇫🇷
Institut Curie, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.